Amyloid-β prediction machine learning model using source-based morphometry across neurocognitive disorders.
Alzheimer’s disease
Amyloid-β
Machine learning
Magnetic resonance imaging
Source-based morphometry
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
12
09
2023
accepted:
26
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
1
4
2024
Statut:
epublish
Résumé
Previous studies have developed and explored magnetic resonance imaging (MRI)-based machine learning models for predicting Alzheimer's disease (AD). However, limited research has focused on models incorporating diverse patient populations. This study aimed to build a clinically useful prediction model for amyloid-beta (Aβ) deposition using source-based morphometry, using a data-driven algorithm based on independent component analyses. Additionally, we assessed how the predictive accuracies varied with the feature combinations. Data from 118 participants clinically diagnosed with various conditions such as AD, mild cognitive impairment, frontotemporal lobar degeneration, corticobasal syndrome, progressive supranuclear palsy, and psychiatric disorders, as well as healthy controls were used for the development of the model. We used structural MR images, cognitive test results, and apolipoprotein E status for feature selection. Three-dimensional T1-weighted images were preprocessed into voxel-based gray matter images and then subjected to source-based morphometry. We used a support vector machine as a classifier. We applied SHapley Additive exPlanations, a game-theoretical approach, to ensure model accountability. The final model that was based on MR-images, cognitive test results, and apolipoprotein E status yielded 89.8% accuracy and a receiver operating characteristic curve of 0.888. The model based on MR-images alone showed 84.7% accuracy. Aβ-positivity was correctly detected in non-AD patients. One of the seven independent components derived from source-based morphometry was considered to represent an AD-related gray matter volume pattern and showed the strongest impact on the model output. Aβ-positivity across neurological and psychiatric disorders was predicted with moderate-to-high accuracy and was associated with a probable AD-related gray matter volume pattern. An MRI-based data-driven machine learning approach can be beneficial as a diagnostic aid.
Identifiants
pubmed: 38561395
doi: 10.1038/s41598-024-58223-3
pii: 10.1038/s41598-024-58223-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7633Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP19dm0307102
Organisme : Japan Agency for Medical Research and Development
ID : JP17pc0101006
Informations de copyright
© 2024. The Author(s).
Références
Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: The amyloid cascade hypothesis. Science 256, 184–185 (1992).
pubmed: 1566067
doi: 10.1126/science.1566067
Jack, C. R. et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).
pubmed: 29653606
doi: 10.1016/j.jalz.2018.02.018
Beach, T. G., Monsell, S. E., Phillips, L. E. & Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J. Neuropathol. Exp. Neurol. 71, 266–273 (2012).
pubmed: 22437338
doi: 10.1097/NEN.0b013e31824b211b
Nichols, E. et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 88–106 (2019).
doi: 10.1016/S1474-4422(18)30403-4
Matsui, Y. et al. Incidence and survival of dementia in a general population of Japanese elderly: The hisayama study. J. Neurol. Neurosurg. Psychiatry. 80, 366–370 (2009).
pubmed: 18977814
doi: 10.1136/jnnp.2008.155481
Hampel, H. et al. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat. Rev. Neurol. 17, 580–589 (2021).
pubmed: 34239130
doi: 10.1038/s41582-021-00520-w
Josephs, K. et al. Relationship between 18 F-flortaucipir uptake and histologic lesion types in 4-repeat tauopathies. J. Nucl. Med. 63, 931–935 (2021).
pubmed: 34556525
doi: 10.2967/jnumed.121.262685
Jack, C. R. et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119–128 (2010).
pubmed: 20083042
doi: 10.1016/S1474-4422(09)70299-6
Jansen, W. J. et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 79, 228–43 (2022).
pubmed: 35099509
doi: 10.1001/jamaneurol.2021.5216
Klunk, W. E. et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306–319 (2004).
pubmed: 14991808
doi: 10.1002/ana.20009
Sabri, O. et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: Phase 3 study. Alzheimers Dement. 11, 964–974 (2015).
pubmed: 25824567
doi: 10.1016/j.jalz.2015.02.004
Blennow, K., Wallin, A. & Agren, H. Tau protein in cerebrospinal fluid. A biochemical marker. Mol. Chem. Neuropathol. 26, 231–245 (1995).
pubmed: 8748926
doi: 10.1007/BF02815140
Zetterberg, H. et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 73, 60–67 (2016).
pubmed: 26524180
doi: 10.1001/jamaneurol.2015.3037
Bun, S. et al. Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status. Alzheimers Res. Ther. 15, 149 (2023).
pubmed: 37667408
doi: 10.1186/s13195-023-01296-5
Chong, J. R. et al. Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: A focused review on recent advances. J. Neurol. Neurosurg. Psychiatry 92, 1231–1241 (2021).
pubmed: 34510001
doi: 10.1136/jnnp-2021-327370
Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: Analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400–418 (2022).
pubmed: 35585226
doi: 10.1038/s41582-022-00665-2
Cummings, J. et al. Lecanemab: Appropriate use recommendations. J. Prev. Alzheimer’s Dis. 10, 362–377 (2023).
Casamitjana, A. et al. MRI-based screening of preclinical Alzheimer’s disease for prevention clinical trials. J. Alzheimers Dis. 64, 1099–1112 (2018).
pubmed: 30010132
doi: 10.3233/JAD-180299
Farrell, M. E. et al. Association of emerging β-amyloid and tau pathology with early cognitive changes in clinically normal older adults. Neurology 98, e1512–e1524 (2022).
pubmed: 35338074
doi: 10.1212/WNL.0000000000200137
Ten Kate, M. et al. MRI predictors of amyloid pathology: Results from the EMIF-AD Multimodal biomarker Discovery study. Alzheimers Res. Ther. 10, 100 (2018).
pubmed: 30261928
doi: 10.1186/s13195-018-0428-1
Frizzell, T. O. et al. Artificial intelligence in brain MRI analysis of Alzheimer’s disease over the past 12 years: A systematic review. Ageing Res. Rev. 77, 101614 (2022).
pubmed: 35358720
doi: 10.1016/j.arr.2022.101614
Habes, M. et al. Disentangling heterogeneity in Alzheimer’s disease and related dementias using data-driven methods. Biol. Psychiatry 88, 70–82 (2020).
pubmed: 32201044
doi: 10.1016/j.biopsych.2020.01.016
Mueller, S. G. et al. Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 1, 55–66 (2005).
pubmed: 17476317
doi: 10.1016/j.jalz.2005.06.003
Sun, Z., Qiao, Y., Lelieveldt, B. P. F. & Staring, M. Alzheimer’s Disease Neuroimaging Initiative. Integrating spatial-anatomical regularization and structure sparsity into SVM: Improving interpretation of Alzheimer’s disease classification. Neuroimage 178, 445–60 (2018).
pubmed: 29802968
doi: 10.1016/j.neuroimage.2018.05.051
Yang, W. et al. Classification of MRI and psychological testing data based on support vector machine HHS Public Access. Int. J. Clin. Exp. Med. 10, 16004 (2017).
pubmed: 29445429
Ezzati, A. et al. Predicting amyloid-β levels in amnestic mild cognitive impairment using machine learning techniques. J. Alzheimers Dis. 73, 1211–1219 (2020).
pubmed: 31884486
doi: 10.3233/JAD-191038
Tosun, D. et al. Detection of β-amyloid positivity in Alzheimer’s Disease neuroimaging initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Commun. 3(2), fcab008 (2021).
pubmed: 33842885
doi: 10.1093/braincomms/fcab008
Kim, J. P. et al. Machine learning based hierarchical classification of frontotemporal dementia and Alzheimer’s disease. NeuroImage Clin. 23, 101811 (2019).
pubmed: 30981204
doi: 10.1016/j.nicl.2019.101811
Zhao, W. et al. Automated brain MRI volumetry differentiates early stages of Alzheimer’s disease from normal aging. J. Geriatr. Psychiatry Neurol. 32, 354–364 (2019).
pubmed: 31480984
doi: 10.1177/0891988719862637
Gupta, C. N., Turner, J. A. & Calhoun, V. D. Source-based morphometry: A decade of covarying structural brain patterns. Brain Struct. Funct. 224, 3031–3044 (2019).
pubmed: 31701266
doi: 10.1007/s00429-019-01969-8
Kunst, J. et al. Patterns of grey matter atrophy at different stages of Parkinson’s and Alzheimer’s diseases and relation to cognition. Brain Topogr. 32, 142–160 (2019).
pubmed: 30206799
doi: 10.1007/s10548-018-0675-2
Li, M. et al. Ameliorative patterns of grey matter in patients with first-episode and treatment-naïve schizophrenia. Psychol. Med. 53, 3500–3510 (2023).
pubmed: 35164887
doi: 10.1017/S0033291722000058
Murley, A. G. et al. Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. Brain 143, 1555–1571 (2020).
pubmed: 32438414
doi: 10.1093/brain/awaa097
Wang, K. C. et al. Brain structural abnormalities in adult major depressive disorder revealed by voxel- and source-based morphometry: Evidence from the Rest-Meta-MDD Consortium. Psychol. Med. 53, 3672–3682 (2023).
pubmed: 35166200
doi: 10.1017/S0033291722000320
Xu, L., Groth, K. M., Pearlson, G., Schretlen, D. J. & Calhoun, V. D. Source-based morphometry: The use of independent component analysis to identify gray matter differences with application to schizophrenia. Hum. Brain Mapp. 30, 711–724 (2009).
pubmed: 18266214
doi: 10.1002/hbm.20540
Shimohama, S. et al. Impact of amyloid and tau PET on changes in diagnosis and patient management. Neurology 100, e264-74 (2023).
pubmed: 36175151
doi: 10.1212/WNL.0000000000201389
Folstein, M. F., Folstein, S. E. & McHugh, P. R. Mini-mental state. J. Psychiatr. Res. 12, 189–198 (1975).
pubmed: 1202204
doi: 10.1016/0022-3956(75)90026-6
Wechsler, D. Wechsler Memory Scale—Revised (Psychological Corporation, 1987).
Borkowski, J. G., Benton, A. L. & Spreen, O. Word fluency and brain damage. Neuropsychologia 5, 135–140 (1967).
doi: 10.1016/0028-3932(67)90015-2
Tombaugh, T. N. Trail Making Test A and B: Normative data stratified by age and education. Arch. Clin. Neuropsychol. 19, 203–214 (2004).
pubmed: 15010086
doi: 10.1016/S0887-6177(03)00039-8
Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer’s disease. Am. J. Psychiatry 141, 1356–1364 (1984).
pubmed: 6496779
doi: 10.1176/ajp.141.11.1356
Matsuoka, K., Uno, M., Kasai, K., Koyama, K. & Kim, Y. Estimation of premorbid IQ in individuals with Alzheimer’s disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry Clin. Neurosci. Jpn. Version 60, 332–339 (2006).
doi: 10.1111/j.1440-1819.2006.01510.x
Morris, J. C. The clinical dementia rating (cdr): Current version and scoring rules. Neurology 43, 2412–2414 (1993).
pubmed: 8232972
doi: 10.1212/WNL.43.11.2412-a
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M. & Filos, S. Measurement of functional activities in older adults in the community. J. Gerontol. 37, 323–9 (1982).
pubmed: 7069156
doi: 10.1093/geronj/37.3.323
Bun, S. et al. Findings of 18 F-PI-2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P-tau181 levels in a Japanese sample. Neuropsychopharmacol. Rep. 42, 437–448 (2022).
pubmed: 35843629
doi: 10.1002/npr2.12281
Tezuka, T. et al. Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Commun. 3, fcab190 (2021).
pubmed: 34632382
doi: 10.1093/braincomms/fcab190
Seibyl, J. et al. Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: Results from a phase-3 study. J. Nucl. Med. 57, 900–906 (2016).
pubmed: 26823561
doi: 10.2967/jnumed.115.161927
Collins, D. L., Neelin, P., Peters, T. M. & Evans, A. C. Automatic 3d intersubject registration of MR volumetric data in standardized Talairach space. J. Comput. Assist. Tomogr. 18, 192–205 (1994).
pubmed: 8126267
doi: 10.1097/00004728-199403000-00005
Caviness, V. S., Lange, N. T., Makris, N., Herbert, M. R. & Kennedy, D. N. MRI-based brain volumetrics: Emergence of a developmental brain science. Brain Dev. 21, 289–295 (1999).
pubmed: 10413014
doi: 10.1016/S0387-7604(99)00022-4
Xia, M., Wang, J. & He, Y. BrainNet Viewer: A network visualization tool for human brain connectomics. PLOS ONE 8, e68910 (2013).
pubmed: 23861951
doi: 10.1371/journal.pone.0068910
Bagarinao, E. et al. An unbiased data-driven age-related structural brain parcellation for the identification of intrinsic brain volume changes over the adult lifespan. Neuroimage 169, 134–144 (2018).
pubmed: 29225065
doi: 10.1016/j.neuroimage.2017.12.014
Pedregosa, F. et al. Scikit-learn: Machine learning in python. J. Mach. Learn. Res. 12, 2825–2830 (2011).
Lundberg, S. M. & Lee, S. I. A unified approach to interpreting model predictions. Adv. Neural Inf. Process. Syst. 2, 4766–4775 (2017).
Frisoni, G. B. et al. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 16, 661–676 (2017).
pubmed: 28721928
doi: 10.1016/S1474-4422(17)30159-X
Cummings, J., Osse, A. M. L., Cammann, D., Powell, J. & Chen, J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. BioDrugs 38, 5–22 (2024).
pubmed: 37955845
doi: 10.1007/s40259-023-00633-2
Veitch, D. P. et al. Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 15, 106–152 (2019).
pubmed: 30321505
doi: 10.1016/j.jalz.2018.08.005
Cavanna, A. E. & Trimble, M. R. The precuneus: A review of its functional anatomy and behavioural correlates. Brain 129, 564–583 (2006).
pubmed: 16399806
doi: 10.1093/brain/awl004
Celone, K. A. et al. Alterations in memory networks in mild cognitive impairment and Alzheimer’s disease: An independent component analysis. J. Neurosci. 26, 10222–10231 (2006).
pubmed: 17021177
doi: 10.1523/JNEUROSCI.2250-06.2006
Wagner, A. D., Shannon, B. J., Kahn, I. & Buckner, R. L. Parietal lobe contributions to episodic memory retrieval. Trends Cogn. Sci. 9, 445–453 (2005).
pubmed: 16054861
doi: 10.1016/j.tics.2005.07.001
Greene, J. D. W., Baddeley, A. D. & Hodges, J. R. Analysis of the episodic memory deficit in early Alzheimer’s disease: Evidence from the doors and people test. Neuropsychologia 34, 537–551 (1996).
pubmed: 8736567
doi: 10.1016/0028-3932(95)00151-4
Salmon, D. P. et al. Alzheimer’s disease can be accurately diagnosed in very mildly impaired individuals. Neurology 59, 1022–1028 (2002).
pubmed: 12370456
doi: 10.1212/WNL.59.7.1022
Baker, J. E. et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimers Dement. (Amst.) 6, 108–121 (2017).
pubmed: 28239636
doi: 10.1016/j.dadm.2016.09.002
LaFerla, F. M., Green, K. N. & Oddo, S. Intracellular amyloid-β in Alzheimer’s disease. Nat. Rev. Neurosci. 8, 499–509 (2007).
pubmed: 17551515
doi: 10.1038/nrn2168
Duara, R. et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 71, 1986–1992 (2008).
pubmed: 19064880
doi: 10.1212/01.wnl.0000336925.79704.9f
Das, S. R. et al. In vivo measures of tau burden are associated with atrophy in early Braak stage medial temporal lobe regions in amyloid-negative individuals. Alzheimers Dement. 15, 1286–1295 (2019).
pubmed: 31495603
doi: 10.1016/j.jalz.2019.05.009
de Flores, R. et al. Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer’s disease. Alzheimers Dement. 16, 843–852 (2020).
pubmed: 32323446
doi: 10.1002/alz.12079
McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 263–269 (2011).
pubmed: 21514250
doi: 10.1016/j.jalz.2011.03.005
Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923 (1993).
pubmed: 8346443
doi: 10.1126/science.8346443
Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960–969 (2011).
pubmed: 22002422
doi: 10.1097/NEN.0b013e318232a379
Habes, M. et al. The Brain Chart of Aging: Machine-learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans. Alzheimers Dement. 17, 89–102 (2021).
pubmed: 32920988
doi: 10.1002/alz.12178
Halevy, A., Norvig, P. & Pereira, F. The reasonable effectiveness of data. IEEE Intell. Syst. 24, 8–12 (2009).
doi: 10.1109/MIS.2009.36
Willemink, M. J. et al. Preparing medical imaging data for machine learning. Radiology 295, 4–15 (2020).
pubmed: 32068507
doi: 10.1148/radiol.2020192224
Marinescu, R. V. et al. DIVE: A spatiotemporal progression model of brain pathology in neurodegenerative disorders. Neuroimage 192, 166–177 (2019).
pubmed: 30844504
doi: 10.1016/j.neuroimage.2019.02.053